Background: This study examined the association of extent of lung resection, pathologic nodal evaluation, and survival for patients with clinical stage I (cT1-2N0M0) adenocarcinoma with lepidic histologic features in the National Cancer Data Base.
Results: Of the 1991 patients with cT1-2N0M0 lepidic adenocarcinoma who met the study criteria, 1544 underwent lobectomy and 447 underwent sublobar resection. Patients treated with sublobar resection were older, more likely to be female, and had higher Charlson/Deyo comorbidity scores, but they had smaller tumors and lower T status. Of the patients treated with lobectomy, 6% (n ¼ 92) were upstaged because of positive nodal disease, with a median of seven lymph nodes sampled (interquartile range [4] [5] [6] [7] [8] [9] [10] . In an analysis of the entire cohort, lobectomy was associated with a significant survival advantage over sublobar resection in univariate analysis (median survival 9.2 versus 7.5 years, p ¼ 0.022, 5-year survival 70.5% versus 67.8%) and after multivariable adjustment (hazard ratio ¼ 0.81, 95% confidence interval: 0.68-0.95, p ¼ 0.011). However, lobectomy was no longer independently associated with improved survival when compared with sublobar resection (hazard ratio ¼ 0.99, 95% confidence interval: 0.77-1.27, p ¼ 0.905) in a multivariable analysis of a subset of patients in which only those patients who had undergone a sublobar resection including lymph node sampling were compared with patients treated with lobectomy.
Conclusions: Surgeons treating patients with stage I lung adenocarcinoma with lepidic features should cautiously utilize sublobar resection rather than lobectomy, and they must always perform adequate pathologic lymph node evaluation.
Introduction
Classification of lung adenocarcinoma has been revised as a result of the increasingly recognized importance of the effect of extent of pathologic tumor invasion on prognosis. Lepidic adenocarcinoma of the lung has well-differentiated histologic features, with tumor growth defined as in situ noninvasive growth along intact alveolar septa, which historically has been referred to as bronchioloalveolar carcinoma.
1-3 Adenocarcinoma with pure lepidic growth and predominant lepidic growth with less than 5-mm invasion are now classified as adenocarcinoma in situ and minimally invasive adenocarcinoma. 3 Rates of lepidic adenocarcinoma have been increasing over the past several decades; however, it remains uncommon, with an estimated incidence of less than 4% of all NSCLC according to data from the Surveillance, Epidemiology, and End Results registry. 4 Lung adenocarcinomas with lepidic histologic features typically have the appearance of ground glass opacity (GGO) on imaging, often occur in nonsmokers, and are increasingly accepted as presenting at earlier stages and behaving less aggressively than other adenocarcinoma subtypes. [5] [6] [7] [8] [9] [10] [11] [12] [13] Accordingly, the diagnosis of lepidic disease typically carries a more favorable prognosis than other adenocarcinoma subtypes do, with disease-specific survival approaching 100% for patients with very small tumors and no evidence of invasion. [14] [15] [16] [17] Although margin-negative anatomic surgical resection with systematic lymph node evaluation is generally considered the standard of care for early-stage NSCLC in qualified patients, studies as to whether a sublobar resection is oncologically equivalent to a lobectomy for pure GGO lesions and minimally invasive adenocarcinomas are being conducted. [18] [19] [20] [21] However, most of the data related to outcomes and treatment for lepidic adenocarcinoma have come from either singleinstitution studies or studies with very homogenous patient populations. The purpose of this study was to examine outcomes after surgical treatment of lepidic adenocarcinoma across a wider spectrum of patients by using a large, nationwide clinical cancer database. The specific goal was to test the primary hypothesis that a lobectomy is associated with better survival than sublobar resection clinical stage I (cT1-2N0M0) lepidic lung adenocarcinoma is. A secondary goal was to examine the practice and impact on outcomes of surgical lymph node sampling when a sublobar resection is utilized.
Methods
The Duke University Institutional Review Board approved this retrospective analysis of the National Cancer Data Base (NCDB). The NCDB is a jointly administered effort by the American Cancer Society and the American College of Surgeons Commission on Cancer that collects data from more than 1500 cancer facilities around the United States. The database currently contains more than 30 million patient records and is estimated to capture approximately 70% of all new cancer diagnoses annually.
Patients who were treated with either lobectomy or sublobar resection for clinical stage I (cT1-2N0M0) lepidic disease in 2003-2006 (the earliest period for which all variables were present and latest survival data) were identified for inclusion on the basis of the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) histologic codes for bronchioloalveolar carcinoma (8250-4) and the Facility Oncology Registry Data Standards procedure codes for lobectomy and sublobar resection. Clinical and pathological stage data were directly extracted on the basis of the sixth edition of the American Joint Committee on Cancer staging criteria. This older system was used rather than the more recent seventh edition because it was the staging system in place at the time of diagnosis and treatment of the disease of patients in the study. Patients were excluded from analysis if they received induction chemotherapy or radiation therapy, as were patients treated with local excision or pneumonectomy.
Patients were stratified by surgical approach, and baseline comparisons of characteristics between the cohort of patients treated with lobectomy and those treated with sublobar resection were performed by using Wilcoxon's rank sum test for continuous variables and Pearson's chi-square test for categorical variables. Patients treated with sublobar resection were then further grouped according to whether they had undergone lymph node sampling as part of their procedure, and similar univariate comparisons were conducted. The primary outcome of interest was long-term survival between groups, which was estimated by the KaplanMeier method. To estimate the independent effect of extent of resection on long-term survival, a multivariable Cox proportional hazards model was developed; it included patient age, sex, race, Charlson/Deyo comorbidity score, and tumor size. Similar survival analyses were then conducted to estimate the effect of lymph node sampling among patients treated with sublobar resection, and to compare survival between patients treated with lobectomy and those treated with sublobar resection that included lymph node sampling.
For all analyses a p value less than 0.05 was considered statistically significant. We made an affirmative decision to control for type I error at the level of all comparisons. Missing data were handled with complete-case analysis in light of the substantial completeness of the NCDB data for the study population. All analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, NC).
Results
A total of 1991 patients with cT1-2N0M0 lepidic adenocarcinoma were identified in the database and met the study criteria; 1544 of these patients (77.5%) underwent lobectomy and 447 (22.5%) were treated with sublobar resection. Of those patients treated with sublobar resection, 374 (83.7%) underwent wedge resections and 73 (16.2%) underwent segmentectomies. The segmentectomy cohort was too small for subgroup analysis. Patients treated with sublobar resection were slightly older (median age 70 versus 69 years), more likely to be female (68.9% versus 63%), and more likely to have a Charlson/Deyo comorbidity score greater than 0 (47.4% versus 36.4%), but they had smaller tumors (median diameter 1.6 versus 2.4 cm) and higher proportions of T1 disease (80.5% versus 67.6%) ( Table 1) .
Of the 1544 patients treated with lobectomy, 1460 (94.6%) also had pathologic lymph node evaluation and 92 (6%) were subsequently upstaged because of positive nodal disease, with a median of seven lymph nodes sampled (interquartile range 4-10, range 1-57). Of those patients who were upstaged, 55 patients (3.6%) were upstaged to N1 and 37 (2.4%) were upstaged to N2. In contrast, lymph node sampling was performed as part of the procedure in only 199 of the patients treated with sublobar resection (45%), with a median of four lymph nodes sampled (interquartile range 2-7, range 1-40). In the sublobar cohort, nodal upstaging occurred in 10 patients (2.2%), with six (1.3%) upstaged to N1 and four (0.9%) upstaged to N2 (see Table 1 ). In the sublobar resection cohort, there were no statistically significant differences in patient or tumor characteristics between patients treated with versus without nodal sampling.
In unadjusted survival analysis of the entire study population (Fig. 1 Table 2) . Similarly, younger age, female sex, white race, lower Charlson/Deyo comorbidity scores, and smaller tumors were all also associated with superior long-term survival.
Among patients treated with sublobar resection, lymph node sampling was associated with substantially improved 5-year survival compared with lack of lymph node sampling (71.1% versus 65.1%). For those patients in whom lymph nodes were not sampled, median survival was 6.5 years, compared with a median survival that was not reached during the study period for patients who underwent lymph node sampling (p ¼ 0.003). After multivariable Cox proportional hazards adjustment, lymph node sampling was associated with a substantially lower hazard of long-term death (HR ¼ 0.68, 95% CI: 0.51-0.92, p ¼ 0.013) in the cohort of patients who had a sublobar resection.
To examine how the addition of lymph node sampling to sublobar resection affected survival compared with lobectomy, survival was compared among the three treatment groups (Fig. 2) , revealing no statistically significant differences in survival between patients treated with sublobar resection that included nodal sampling and lobectomy (HR ¼ 0.93, 95% CI: 0.73-1.19, p ¼ 0.56) but markedly worse survival for patients treated with sublobar resection that did not include nodal sampling than for patients treated with lobectomy (HR ¼ 1.45, 95% CI: 1.20-1.76, p < 0.001). Furthermore, in a multivariable Cox proportional hazards model including only those patients treated with lobectomy or sublobar resection that included lymph node sampling, extent of resection (lobectomy versus sublobar resection) was no longer independently associated with survival (HR ¼ 0.99, 95% CI: 0.77-1.27, p ¼ 0.905) ( Table 3 ).
Discussion
In this study utilizing the NCDB to assemble a large cohort of patients who underwent resection of clinical stage I lung adenocarcinoma with lepidic histologic features, we found that lobectomy was used in most patients and associated with significantly better longterm survival than sublobar resection was in both univariate and multivariate analysis. In this cohort of patients with what is generally considered a favorable prognosis in terms of oncologic outcomes, we observed a rate of pathologic nodal upstaging of 6% in patients who underwent lobectomy. Although sublobar resection was used in a minority of patients in the overall cohort, our results suggest that appropriate oncologic principles were often not followed when sublobar resection was utilized, as less than half of these patients had pathologic lymph node analysis. The rate of nodal upstaging for sublobar resection patients who did have nodal evaluation was low, but still 2.2%. Interestingly, survival when sublobar resection included lymph node sampling was not significantly different than survival after lobectomy, suggesting that pathologic nodal sampling is an essential aspect of appropriate surgical oncologic management when sublobar resection is considered or utilized. The management of predominantly GGO lung lesions, which generally correlate with lepidic predominant lesions histologically, has been reasonably well studied in terms of both when to treat and the extent of resection. 12, 22 For early-stage disease, surgical resection remains the preferred treatment. 18 A sublobar resection has been suggested to be oncologically equivalent to a lobectomy for pure GGO lesions and minimally invasive adenocarcinomas (corresponding to a solid component with a diameter of >5 mm). [19] [20] [21] A number of singlecenter studies have examined the extent of surgical resection in this patient population and how it effects survival. Although all of these studies were conspicuously small, with relevant sample sizes ranging from 17 to 80 patients, there was no difference in long-term survival for sublobar resection compared with lobectomy among early-stage patients. 1, [23] [24] [25] Notably, these small studies typically have had relatively homogeneous patient populations, and as such, their results may not be truly generalizable to other types of patients. Our main finding of significantly improved survival after lobectomy compared with after sublobar resection suggests that the choice to perform a sublobar resection rather than a lobectomy should be made only with great care. Our study does have some very interesting findings related to nodal staging. First, the rate of nodal upstaging in the setting of clinically node-negative patients is low but not zero in this cohort of patients in whom nodal disease is generally believed to be unlikely. This finding may have implications for when nonsurgical therapy with stereotactic ablative radiation therapy is considered. 26 Patients should be counseled that there is a small but real chance that that local therapy alone will be inadequate treatment. Second, the finding that performing nodal evaluation at the time of sublobar resection improves survival is also very interesting. Conceptually explaining why nodal sampling would improve outcomes is difficult, even if nodal removal is itself actually therapeutic or if identifying a positive node leads to adjuvant therapy that improves prognosis given the small overall rate of nodal upstaging in the cohort. However, this phenomenon has been observed before. In a study of NSCLC not limited to lepidic disease, Wolf et al. demonstrated that overall and recurrence-free survival rates after sublobar resection were similar to those after lobectomy as long as lymph nodes were sampled at the time of sublobar resection. 27 Although our results demonstrate that only 5.1% of stage I patients are subsequently upstaged because of nodal disease, the addition of lymph node sampling to sublobar resection is associated with a clear survival benefit. The addition of lymph node sampling may be a marker indicating that a more appropriate oncologic procedure was performed April 2017 Assessing Pulmonary Lepidic Adenocarcinomanot only in regard to lymph node evaluation but also in regard to achieving appropriate margins to ensure adequate resection. However, it is also possible that there was selection bias for patients in whom lymph node evaluation was not performed in that surgeons preferentially did not sample or dissect lymph nodes because they believed that the patient's overall prognosis was very poor irrespective of lymph node status or that the patient's clinical status was impaired such that adjuvant chemotherapy was not a possibility regardless of lymph node involvement. In any case, our findings mandate that lymph node evaluation be conducted when lepidic adenocarcinoma is surgically resected.
Our findings indicate that sublobar resection with nodal sampling may be an acceptable alternative to lobectomy in select cases. This is particularly relevant in the context of our aging patient population. The median patient age in our national study cohort was 69 years, with 39% of patients bearing substantial medical comorbidities (Charlson/Deyo score 1). Given this advanced age and comorbidity burden, sublobar resection offers numerous potential advantages. Potential advantages include preservation of pulmonary function and lower incidence of perioperative morbidity. 28 However, as already mentioned, the decision to choose intentional sublobar resection even for lepidic adenocarcinoma should be made very carefully, especially until data from randomized trials comparing lobectomy and sublobar resection become available for analysis. 21 It should be noted that there is a crossing of sublobar and lobectomy survival curves after about 3 years, at which point the survival time for sublobar patients is slightly better in the earlier period, but it then becomes significantly worse than the survival time for lobectomy patients. Clinically, the slight early advantage observed for sublobar resections could be due to slightly higher procedural morbidity for lobectomy patients. The poorer survival after 3 years could be due to the other comorbid conditions for the sublobar patients, although it was in this later time period that the benefit of lobectomy over sublobar resection for early-stage lung cancer was noted to become apparent in the landmark randomized lung cancer study group trial that established lobectomy as the definitive standard surgical therapy for clinical stage IA NSCLC. 29 Although lepidic adenocarcinoma often presents as a multifocal disease, our study focuses on stage I disease, not only limiting our results to the management of solitary nodules but also allowing for clinical equipoise between lobectomy and sublobar resection. 30 It should be noted that our results are applicable to patients who have pathologically proven lepidic adenocarcinoma, which is not necessarily known prior to definitive surgical treatment. In a clinical setting, our results are most applicable in the treatment settings in which the likelihood of a lepidic histologic subtype is considered high because of radiographic appearance, race, and smoking history.
This study does have inherent limitations associated with its retrospective nature. Although multivariable regression can adjust for measured covariates, residual unmeasured confounding cannot be excluded. The NCDB does not identify reasons for specific surgical approaches and extent of resection, and it is possible that treatment was planned as a sublobar resection on the basis of tumor characteristics. Conversely, some of the patients treated with lobectomy were likely never candidates for sublobar resection because of a more central tumor location, which may have biased our results in favor of sublobar resection if the prognosis for central tumors was not equivalent to that for peripheral tumors. In addition, the multivariable analysis with adjustments for age, tumor size, and comorbidities attempted to control for selection bias, but there is still a chance that there were unmeasured characteristics that could not controlled for and lobectomy may have been preferentially chosen for healthier patients or for those who were clinically believed to have a good chance at longevity with a lung cancer cure. Therefore, we may be overestimating the benefit of lobectomy over sublobar treatment, and this could be supported by our late crossing survival curves (see Fig. 1 ). Similarly, segmentectomies and wedge resections were considered together as sublobar resections because most sublobar resections in the cohort were wedge resections and the segmentectomy group was too small for subgroup analysis. However, some studies have suggested that segmentectomy may be oncologically superior for NSCLC and our results are most likely applicable to a comparison between lobectomy and wedge resection. 31, 32 The use of NCDB registry data inherently also precludes knowing the degree of lepidic histologic features, including the amount of GGO involvement or degree of microscopic invasiveness. Several studies have shown that the solid diameter of a part-solid lesion is more predictive of biology than the total diameter of the lesion. 7, 8, [33] [34] [35] [36] It is possible that the distribution of lepidic histologic features in the tumors in each group was not balanced. Therefore, our results are applicable only to adenocarcinomas with lepidic histologic features and an invasive component based on histologic features and tumor behavior known at the time of treatment. We cannot comment on the impact of changes in lepidic tumor size over time for lesions that were watched for a period of time with serial imaging before surgical treatment.
Lepidic adenocarcinoma also often presents as a multifocal disease, and therefore, the presence of other radiographic abnormalities may have influenced the choice of surgical treatment. 11, 30, 37, 38 Given the lack of radiographic characteristics within the NCDB, our analysis was not able to adjust for this potential clinical feature. Likewise, the extent of lymph node analysis in terms of dissection versus sampling is unknown. The actual lymph node count has been previously questioned, given the variability across pathological processing. However, we have included the absolute count, allowing readers to make their own inference as to the extent of lymph node assessment.
In addition, the NCDB contains limited data regarding patient comorbidities and no information regarding pulmonary function measurements and functional status. We also did not have access to data regarding the presence of an EGFR mutation or the anaplastic lymphoma kinase (ALK) fusion oncogene. Although both of these have been implicated as important in guiding postoperative management of lepidic lung cancer, this is likely less important given the early stage of disease in our population. 39, 40 Additionally, the NCDB lacks details regarding the staging modalities used to establish a clinical stage I diagnosis. Rates of clinical understaging may have differed between groups if availability of staging modalities was not balanced between patients treated with lobectomy and sublobar resection. Similarly, changes during the study period in use of staging modalities may have led to systematic variations in stage migration over time, particularly as endobronchial ultrasound and positron emission tomography may have increased in use toward the latter years of the study. Lastly, the study may not necessarily be generalizable to all stage 1 patients. In this study, both T1 and T2 patients were included in the analysis because the objective of the study was to consider the impact of extent of resection on outcomes for lepidic adenocarcinoma in situations in which the clinical node status was negative, because both surgical procedures are often feasible for patients with radiographic suggestion of lepidic histologic features regardless of tumor size. Separate T1 and T2 subgroup analyses were not performed because the sample size for the T2 subgroup of the sublobar resection cohort was relatively small (N ¼ 87). However, the Cox survival model results regarding the effect of surgery on survival were found to be stable even when clinical T factor was added as a potential predictor (data not shown), suggesting that the results were not biased by one type of surgery being used preferentially for T1 or T2 lesions.
Despite these limitations, the NCDB has the considerable strength of being powered to investigate a relatively uncommon pathologic subtype of NSCLC within a specific cancer substage. In light of the uncommon nature of lepidic adenocarcinoma, even if a randomized prospective trial were to be conducted among early-stage patients, such a trial would enroll orders of magnitude fewer patients than the present study, thereby emphasizing the generalizability of our results. On the basis of these results, providers can utilize our data when evaluating patients who, on the basis of their experience and clinical assessment, are believed to have a high probability of having lepidic histologic features. Surgeons should utilize sublobar resection only very carefully and must always include adequate lymph node evaluation when treating patients with stage I lung adenocarcinoma with lepidic features.
